GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti announced a class action lawsuit against GeneDx Holdings regarding alleged securities fraud tied to the acquisition of Fabric Genomics and subsequent financial performance. The complaint centers on disclosures made on May 4, 2026, where the company missed revenue estimates, reported a drop in adjusted gross margin to 69%, and lowered full-year revenue guidance to $475-$490 million.
Key figures
- Guidance
- $475 - $490 million, down from $540 - $550 million
- Stock decline
- 49.2% or $33.42 per share
- Impairment loss
- $31.2 million
- Adjusted gross margin decline
- 74% to 69%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.